Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium

PURPOSE: Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically with rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment-naive patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: James, Danelle F., Werner, Lillian, Brown, Jennifer R., Wierda, William G., Barrientos, Jacqueline C., Castro, Januario E., Greaves, Andrew, Johnson, Amy J., Rassenti, Laura Z., Rai, Kanti R., Neuberg, Donna, Kipps, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067945/
https://ncbi.nlm.nih.gov/pubmed/24868031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.5890
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados